Education
About Us
Working with TipRanks
Follow Us
Atricure (ATRC)
NASDAQ:ATRC
Earnings Data
Report Date
May 05, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.14Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights strong revenue growth (FY2025 +14.9%), significant profitability improvement (adjusted EBITDA nearly doubled vs. prior year), solid cash generation, multiple product and clinical milestones (LeAAPS enrollment completed, BoxX‑NoAF launched, EnCompass adoption, new product launches), and reaffirmed 2026 guidance. Offsetting these positives are meaningful headwinds in the minimally invasive/hybrid Afib franchise driven by rapid PFA adoption, localized reimbursement challenges in the U.K., and new competitive entrants in the appendage market. Management expects the MIS pressure to moderate and has modeled modest competitive impacts into guidance while emphasizing operating leverage and continued investment in clinical evidence and innovation.Company Guidance
Strong Full Year Revenue Growth and Beat
Total revenue for FY2025 was $534.5 million, up 14.9% reported and 14.4% constant currency vs. 2024 — above the company’s initial 2025 guidance (11%–13%).
Quarterly Revenue Momentum
Q4 2025 revenue was $140.5 million, up 13.1% reported and 12.1% constant currency vs. Q4 2024; sequential Q4 vs Q3 sales grew $6.2 million (4.6%).
Material Profitability Improvement
Adjusted EBITDA for FY2025 was $61.8 million vs. $31.1 million in 2024 (+$30.6M). Q4 adjusted EBITDA was $19.9 million vs. $12.7 million in Q4 2024. The company delivered positive net income in Q4 ($1.8M) versus a $15.6M net loss in Q4 2024.
Improved Margins and Cash Generation
Gross margin was 75% for both Q4 and FY2025, up 45 basis points in Q4 and 29 basis points for the year vs. 2024. Full year cash generation was approximately $45 million, and year-end cash & investments totaled $167.4 million.
Robust Pain Management Franchise Expansion
Pain management worldwide revenue grew 33% for FY2025 and 24% in Q4, driven by cryoSPHERE MAX adoption. The company ended the year with ~500 U.S. accounts using cryoSPHERE MAX and reported >100,000 patients treated with cryoSPHERE probes since launch (2019).
Appendage Management Growth Led by FLEX‑Mini
Worldwide left atrial appendage franchise revenue grew 19% for FY2025 and 15% in Q4. Open appendage management grew ~24% in the U.S.; AtriClip FLEX‑Mini contributed ~18% of worldwide left atrial appendage revenue and >300 active accounts were purchasing FLEX‑Mini.
Open Ablation Strength and EnCompass Adoption
Open ablation grew >17% in Q4 and for FY2025, with EnCompass Clamp the primary driver. EnCompass is present in over 830 accounts worldwide and contributed >60% of U.S. open ablation revenue.
Clinical and R&D Milestones: Large Trials and New Products
LeAAPS trial completed enrollment (~6,573 patients; >500 surgeons across 137 sites). BoxX‑NoAF trial (960 patients) launched. First‑in‑human treatments completed for the dual‑energy EnCompass in Dec. Two product launches in 2025 (AtriClip PRO Mini, cryoXT PRO) and cryoXT launched for pain/amputation in Q3 2025.
2026 Guidance Reaffirmed
Management reaffirmed 2026 revenue guidance of $600M–$610M (12%–14% growth) and adjusted EBITDA guidance of $80M–$82M, plus full year net income and adjusted EPS guidance of $0.09–$0.15.
Operating Leverage and Expense Discipline
Full year operating expenses increased 5.9% vs. 13% top‑line growth; SG&A grew 6.7% (below revenue growth). R&D spend is moderating as LeAAPS enrollment completed; management expects R&D to grow in the low‑teens organically in 2026, but overall OpEx leverage is improving.
ATRC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ATRC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 17, 2026 | $32.97 | $32.26 | -2.15% |
Oct 29, 2025 | $35.44 | $34.09 | -3.81% |
Jul 29, 2025 | $31.73 | $35.13 | +10.72% |
Apr 29, 2025 | $34.65 | $29.91 | -13.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Atricure (ATRC) report earnings?
Atricure (ATRC) is schdueled to report earning on May 05, 2026, After Close (Confirmed).
What is Atricure (ATRC) earnings time?
Atricure (ATRC) earnings time is at May 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ATRC EPS forecast?
ATRC EPS forecast for the fiscal quarter 2026 (Q1) is -0.07.